Ambarella Inc vs American Well Corp — how do they compare? Ambarella Inc trades at $83 (market cap $3.60B), while American Well Corp trades at $13.5 (market cap $230.98M). The key difference: Ambarella Inc is far larger — about 15.6× American Well Corp's market cap, and American Well Corp is trading nearer its 52-week high, Ambarella Inc nearer its low. Which is the better fit depends on your goals.
| AMBA | AMWL | |
|---|---|---|
Market Cap | $3.60B | $230.98M |
Sector | Technology | Health |
52-Week High | $95.51 | $13.58 |
52-Week Low | $48.65 | $3.78 |
Enterprise Value | $3.33B | $38.01M |
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $86.78, up 3.57% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics. Recent news highlights NXP's potential acquisition interest and the company's strategic pivot to edge AI chips, driving analyst optimism. Q2 2026 earnings are expected at $0.171 per share, following three consecutive quarterly beats. Revenue growth is projected to accelerate from $285M in 2025 to $405M in 2026.
Outlook remains positive with 58% analyst buy ratings and $108.67 price target, but risks include persistent net losses, high valuation multiples, and competitive pressure in semiconductor space. The edge AI transition offers growth potential, yet execution risks and insider selling warrant caution for investors.
AMWL (American Well Corporation) trades at $13.52, up 4.56% today, with a bullish technical signal from moving averages. The company shows improving financial trends with narrowing losses—net income margin improved from -97.57% in 2022 to -35.75% in 2026—and positive earnings beats in recent quarters. Recent news highlights include a Defense Health Agency partnership intent and leadership changes at Amazon's healthcare unit involving an Amwell co-founder. Operating cash flow losses have decreased significantly from -$192M in 2022 to -$26M projected for 2026.
Outlook: AMWL's path to operating breakeven by Q4 2026 and reduced cash burn present a turnaround opportunity, but persistent revenue declines and negative margins pose risks. Analyst sentiment is mixed with 33% buy ratings. The stock's valuation at P/S of 1.02 appears reasonable if growth resumes, but execution on profitability targets is critical for sustained upside.
Trailing returns across standard periods
Latest headlines on both assets
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →